From Safe Bets to Purposeful Impact: How the Gilead Foundation Pivoted Back to Patients

From Safe Bets to Purposeful Impact: How the Gilead Foundation Pivoted Back to Patients
Share

Gilead Sciences is a biopharmaceutical company that has spent more than three decades developing medicines for life-threatening diseases. It is best known for its work in HIV and viral hepatitis and has since expanded into oncology and inflammation. With roughly 17,000 employees and operations in more than 35 countries, Gilead is one of the largest biotech companies in the world, and its philanthropic arm, the Gilead Foundation, extends that mission beyond the lab.

The Problem: Impact without Strategic Fit

Gilead Foundation Logo

For more than two decades the Gilead Foundation quietly funded causes it believed would improve health, most recently education, a proven social determinant of better health outcomes and well-being. It was a safe, respectable approach: cash grants, employee volunteering, and steady support for long-term change. But by 2025 the Foundation’s leaders realized something important: those efforts, while worthy, were not where the Foundation or the company was best placed to make a difference.

Jane Stafford, President of the Gilead Foundation, remembers the turning point plainly. Education equity mattered, but it didn’t resonate deeply with Gilead employees as few were education experts, and it couldn’t tap into the company’s core expertise in health. The grants portfolio lacked common KPIs and a shared aim. The Foundation was doing good, but not in a way that reflected the company’s reason for being: Creating a healthier world for all people.

The Turning Point: Re-centering on Patients

The pivot began with a simple question: what would happen if the Foundation leaned closer to the company’s lived experience while remaining scrupulously independent? That experience includes deep knowledge of therapies and health systems and, above all, a long history of working directly with patients and communities. Interestingly, the Foundation’s early grants focused on patients, a focus that diminished over the years.

Working with FSG, the Gilead Foundation returned to its roots: patients and their communities. Gilead drew on three inputs: insights from a landscape analysis, inspiration from a benchmarking study of innovative approaches in the field, and FSG’s guidance on how corporate foundations can look beyond cash to other company assets to create impact. The Gilead Foundation combined these with something it already had: Gilead’s long legacy of engaging directly with patients and communities. That engagement had given the company a grounded understanding of the patient journey, the gaps in access to care, and what communities themselves say they need most. This understanding sharpened the strategic direction and led to smarter, more targeted interventions that could improve both near- and long-term health outcomes.

Moving closer to the business meant the Foundation had to protect its independence. The Foundation’s board, not the company, owned the strategy, and the board’s chair, who also serves as Gilead’s General Counsel, helped ensure the line between purposeful philanthropy and self-dealing stayed clear. While reporting and oversight always require careful navigation, the Board provided the right guardrails that allowed for a bolder approach.

Communications: From Strategy to Story

Real Chemistry, a healthcare communications firm, helped translate the reimagined strategy into a story people could feel and make their own. The result: a narrative to “Make Better Health Possible” that employees could champion, partners could rally around, and communities could trust.

Today, the Gilead Foundation’s work is closely aligned with the company’s health expertise, rigorously governed, and sharply focused on patient-centered outcomes. It’s a reminder that corporate foundations can be both principled and strategic, using unique insights to amplify social impact without compromising their philanthropic integrity.

“Bringing the Foundation back to patients and the patient community, while maintaining independence, allowed us to lean closer to the company’s purpose without compromising the foundation’s social impact mission,” Jane Stafford reflects.

Related Case Studies

View All Case Studies
Close

Sign Up to Download

You will also receive email updates on new ideas and resources from FSG.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Already signed up? Enter your email

Confirm Your Registration

You will also receive email updates on new ideas and resources from FSG.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Secret Link